FDA
-
-
-
-
-
-
-
Vaxcyte publishes positive VAX-31 phase 1/2 data in Lancet study
-
-
-
-
-
-
-
Evercore ISI on Vaxcyte (PCVX): 'vaccine shakeup, but there's no change to PCV recs...'
-
-
-
-
-
-
-
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
-
-
-
-
-
-
-
Vaxcyte, Inc (PCVX) Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
-
-
-
-
-
-
-
Vaxcyte, Inc (PCVX) Provides Regulatory Updates on VAX-31 Pediatric and Adult Programs
-
-
-
-
-
-
-
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
-
330,681 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

